Detection of Phenethylamine, Amphetamine, and Tryptamine Imine By-Products from an Acetone Extraction
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Neurotransmitter Resource Guide
NEUROTRANSMITTER RESOURCE GUIDE Science + Insight doctorsdata.com Doctor’s Data, Inc. Neurotransmitter RESOURCE GUIDE Table of Contents Sample Report Sample Report ........................................................................................................................................................................... 1 Analyte Considerations Phenylethylamine (B-phenylethylamine or PEA) ................................................................................................. 1 Tyrosine .......................................................................................................................................................................................... 3 Tyramine ........................................................................................................................................................................................4 Dopamine .....................................................................................................................................................................................6 3, 4-Dihydroxyphenylacetic Acid (DOPAC) ............................................................................................................... 7 3-Methoxytyramine (3-MT) ............................................................................................................................................... 9 Norepinephrine ........................................................................................................................................................................ -
Methylphenidate Hydrochloride
Application for Inclusion to the 22nd Expert Committee on the Selection and Use of Essential Medicines: METHYLPHENIDATE HYDROCHLORIDE December 7, 2018 Submitted by: Patricia Moscibrodzki, M.P.H., and Craig L. Katz, M.D. The Icahn School of Medicine at Mount Sinai Graduate Program in Public Health New York NY, United States Contact: [email protected] TABLE OF CONTENTS Page 3 Summary Statement Page 4 Focal Point Person in WHO Page 5 Name of Organizations Consulted Page 6 International Nonproprietary Name Page 7 Formulations Proposed for Inclusion Page 8 International Availability Page 10 Listing Requested Page 11 Public Health Relevance Page 13 Treatment Details Page 19 Comparative Effectiveness Page 29 Comparative Safety Page 41 Comparative Cost and Cost-Effectiveness Page 45 Regulatory Status Page 48 Pharmacoepial Standards Page 49 Text for the WHO Model Formulary Page 52 References Page 61 Appendix – Letters of Support 2 1. Summary Statement of the Proposal for Inclusion of Methylphenidate Methylphenidate (MPH), a central nervous system (CNS) stimulant, of the phenethylamine class, is proposed for inclusion in the WHO Model List of Essential Medications (EML) & the Model List of Essential Medications for Children (EMLc) for treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) under ICD-11, 6C9Z mental, behavioral or neurodevelopmental disorder, disruptive behavior or dissocial disorders. To date, the list of essential medications does not include stimulants, which play a critical role in the treatment of psychotic disorders. Methylphenidate is proposed for inclusion on the complimentary list for both children and adults. This application provides a systematic review of the use, efficacy, safety, availability, and cost-effectiveness of methylphenidate compared with other stimulant (first-line) and non-stimulant (second-line) medications. -
Part I: Carbonyl-Olefin Metathesis of Norbornene
Part I: Carbonyl-Olefin Metathesis of Norbornene Part II: Cyclopropenimine-Catalyzed Asymmetric Michael Reactions Zara Maxine Seibel Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in the Graduate School of Arts and Sciences COLUMBIA UNIVERSITY 2016 1 © 2016 Zara Maxine Seibel All Rights Reserved 2 ABSTRACT Part I: Carbonyl-Olefin Metathesis of Norbornene Part II: Cyclopropenimine-Catalyzed Asymmetric Michael Reactions Zara Maxine Seibel This thesis details progress towards the development of an organocatalytic carbonyl- olefin metathesis of norbornene. This transformation has not previously been done catalytically and has not been done in practical manner with stepwise or stoichiometric processes. Building on the previous work of the Lambert lab on the metathesis of cyclopropene and an aldehyde using a hydrazine catalyst, this work discusses efforts to expand to the less stained norbornene. Computational and experimental studies on the catalytic cycle are discussed, including detailed experimental work on how various factors affect the difficult cycloreversion step. The second portion of this thesis details the use of chiral cyclopropenimine bases as catalysts for asymmetric Michael reactions. The Lambert lab has previously developed chiral cyclopropenimine bases for glycine imine nucleophiles. The scope of these catalysts was expanded to include glycine imine derivatives in which the nitrogen atom was replaced with a carbon atom, and to include imines derived from other amino acids. i Table of Contents List of Abbreviations…………………………………………………………………………..iv Part I: Carbonyl-Olefin Metathesis…………………………………………………………… 1 Chapter 1 – Metathesis Reactions of Double Bonds………………………………………….. 1 Introduction………………………………………………………………………………. 1 Olefin Metathesis………………………………………………………………………… 2 Wittig Reaction…………………………………………………………………………... 6 Tebbe Olefination………………………………………………………………………... 9 Carbonyl-Olefin Metathesis……………………………………………………………. -
Federal Register/Vol. 70, No. 42/Friday, March 4, 2005
Federal Register / Vol. 70, No. 42 / Friday, March 4, 2005 / Notices 10677 Drug Schedule Drug Schedule Therefore, pursuant to 21 U.S.C. 823, and in accordance with 21 CFR 1301.33, Cathinone (1235) .......................... I Alpha-Methylfentanyl (9814) ........ I the above named company is granted Methcathinone (1237) .................. I Acetyl-alpha-methylfentanyl I registration as a bulk manufacturer of N-Ethylamphetamine (1475) ........ I (9815). the basic classes of controlled N,N-Dimethylamphetamine (1480) I Beta-hydroxyfentanyl (9830) ........ I substances listed. Aminorex (1585) ........................... I Beta-hydroxy-3-methylfentanyl I 4-7Methylaminorex (cis isomer) I (9831). Dated: Febuary 22, 2005. (1590). Alpha-Methylthiofentanyl (9832) ... I William J. Walker, Gamma hydroxybutyric acid I 3–Methylthiofentanyl (9833) ......... I Deputy Assistant Administrator, Office of Thiofentanyl (9835) ...................... I (2010). Diversion Control, Drug Enforcement Amphetamine (1100) .................... II Methaqualone (2565) ................... I Administration. Alpha-Ethyltryptamine (7249) ....... I Methamphetamine (1105) ............ II Lysergic acid diethylamide (7315) I Phenmetrazine (1631) .................. II [FR Doc. 05–4205 Filed 3–3–05; 8:45 am] Tetrahydrocannabinols (7370) ..... I Methylphenidate (1724) ................ II BILLING CODE 4410–09–P Mescaline (7381) .......................... I Ambobarbital (2125) ..................... II 3,4,5-Trimethoxyamphetamine I Pentobarbital (2270) ..................... II (7390). -
SENATE BILL No. 259 No
SENATE BILL No. 259 SENATE BILL No. 259 March 10, 2011, Introduced by Senators JONES, CASPERSON and SCHUITMAKER and referred to the Committee on Judiciary. A bill to amend 1978 PA 368, entitled "Public health code," by amending section 7212 (MCL 333.7212), as amended by 2010 PA 171. THE PEOPLE OF THE STATE OF MICHIGAN ENACT: 1 Sec. 7212. (1) The following controlled substances are 2 included in schedule 1: 3 (a) Any of the following opiates, including their isomers, 4 esters, the ethers, salts, and salts of isomers, esters, and 5 ethers, unless specifically excepted, when the existence of these 6 isomers, esters, ethers, and salts is possible within the 7 specific chemical designation: SENATE BILL No. 259 00981'11 TLG 2 1 Acetylmethadol Difenoxin Noracymethadol 2 Allylprodine Dimenoxadol Norlevorphanol 3 Alpha-acetylmethadol Dimepheptanol Normethadone 4 Alphameprodine Dimethylthiambutene Norpipanone 5 Alphamethadol Dioxaphetyl butyrate Phenadoxone 6 Benzethidine Dipipanone Phenampromide 7 Betacetylmethadol Ethylmethylthiambutene Phenomorphan 8 Betameprodine Etonitazene Phenoperidine 9 Betamethadol Etoxeridine Piritramide 10 Betaprodine Furethidine Proheptazine 11 Clonitazene Hydroxypethidine Properidine 12 Dextromoramide Ketobemidone Propiram 13 Diampromide Levomoramide Racemoramide 14 Diethylthiambutene Levophenacylmorphan Trimeperidine 15 Morpheridine 16 (b) Any of the following opium derivatives, their salts, 17 isomers, and salts of isomers, unless specifically excepted, when 18 the existence of these salts, isomers, and salts of -
3,4-Methylenedioxymethcathinone (Methylone) [“Bath Salt,” Bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019
Drug Enforcement Administration Diversion Control Division Drug & Chemical Evaluation Section 3,4-Methylenedioxymethcathinone (Methylone) [“Bath salt,” bk-MDMA, MDMC, MDMCAT, “Explosion,” “Ease,” “Molly”] December 2019 Introduction: discriminate DOM from saline. 3,4-Methylenedioxymethcathinone (methylone) is a Because of the structural and pharmacological similarities designer drug of the phenethylamine class. Methylone is a between methylone and MDMA, the psychoactive effects, adverse synthetic cathinone with substantial chemical, structural, and health risks, and signs of intoxication resulting from methylone pharmacological similarities to 3,4-methylenedioxymeth- abuse are likely to be similar to those of MDMA. Several chat amphetamine (MDMA, ecstasy). Animal studies indicate that rooms discussed pleasant and positive effects of methylone when methylone has MDMA-like and (+)-amphetamine-like used for recreational purpose. behavioral effects. When combined with mephedrone, a controlled schedule I substance, the combination is called User Population: “bubbles.” Other names are given in the above title. Methylone, like other synthetic cathinones, is a recreational drug that emerged on the United States’ illicit drug market in 2009. It is perceived as being a ‘legal’ alternative to drugs of Licit Uses: Methylone is not approved for medical use in the United abuse like MDMA, methamphetamine, and cocaine. Evidence States. indicates that youths and young adults are the primary users of synthetic cathinone substances which include methylone. However, older adults also have been identified as users of these Chemistry: substances. O H O N CH3 Illicit Distribution: CH O 3 Law enforcement has encountered methylone in the United States as well as in several countries including the Netherlands, Methylone United Kingdom, Japan, and Sweden. -
(19) United States (12) Patent Application Publication (10) Pub
US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist. -
SYNTHESIS and PROPERTIES of SOME ARALKYL Hymoperoxides
SYNTHESIS AND PROPERTIES OF SOME ARALKYL HYmOPEROXIDES DISSERTATION Presented in Partial Fulfillment of the Requirements for the Degree Doctor of Philosophy in the Graduate School of The Ohio State University By ARLO d / bCGGS, B.S., M.S. The Ohio State University 1954 Approved by: Department of Chemistry ACKNOWLEDGEMENT The author wishes to express sincere appreciation to Professor Cecil E. Boord for his advice and counsel during this investigation* Thanks also are due Dr. Kenneth W*. Greenlee for his continual interest and guidance and his cooperation in ex tending the facilities of the American Petroleum Institute Research Project 4-5* The financial support of this work by the Firestone Tire and Rubber Company is gratefully acknowledged* ii TABLE OF CONTENTS Page I. INTRODUCTION................................ 1 II. LITERATURE S URVEY ............... 2 III. STATEMENT OF THE PROBLEM.................... 10 IV. DISCUS5IŒ ........................... 11 A. Methods of Preparing Hydroperoxides .... 12 1. Preparation of hydroperoxides from alcohols ............. 12 a. a-methylbenzyl hydroperoxide ...... 12 b. benzyl hydroperoxide .......... l6 c. cinnamyl and a-phenylallyl hydroperoxides 17 d. 1,2,3,4-tetrahydro-l-naphthyl hydro peroxide ............ 22 e. a-indanyl hydroperoxide ........ 23 f. 0-, m- and p-methylbenzyl hydroperoxides 24 g. m- and p-methoxybenzyl hydroperoxides. 28 h. 1,1-diphenylmethyl hydroperoxide .... 31 i. 1,2-diphenylethyl hydroperoxide .... 32 j. 1-a-naphthyl- and l-J3-naphthylethyl hydroperoxides ........ 33 k. 1-styrylethyl hydroperoxide 35 1. 4-a-dimethylbenzyl and 4-methoxy-a- methylbenzyl hydroperoxides ...... 36 m. a-ethylbenzyl and a-ethyl-p-methylbenzyl hydroperoxides ....... ........ 36 n. a-n-propylbenzyl and a-isopropylbenzyl hydroperoxides .................... 37 0. a-2,5“trimethylbenzyl hydroperoxide . -
Comparison of the Characteristic Mass Fragmentations of Phenethylamines and Tryptamines by Electron Ionization Gas Chromatograph
applied sciences Article Comparison of the Characteristic Mass Fragmentations of Phenethylamines and Tryptamines by Electron Ionization Gas Chromatography Mass Spectrometry, Electrospray and Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Bo-Hong Chen, Ju-Tsung Liu, Hung-Ming Chen, Wen-Xiong Chen and Cheng-Huang Lin * Department of Chemistry, National Taiwan Normal University, 88 Sec. 4 Tingchow Road, Taipei 11677, Taiwan; [email protected] (B.-H.C.); [email protected] (J.-T.L.); [email protected] (H.-M.C.); [email protected] (W.-X.C.) * Correspondence: [email protected]; Tel.: +886-2-7734-6170; Fax: +886-2-2932-4249 Received: 18 April 2018; Accepted: 19 June 2018; Published: 22 June 2018 Abstract: Characteristic mass fragmentation of 20 phenethylamine/tryptamine standards were investigated and compared by means of matrix assisted laser desorption/time-of-flight mass spectrometry (MALDI/TOFM), gas chromatography–electron ionization–mass spectrometry (GC-EI/MS) and liquid chromatography–electrospray ionization/mass spectrometry (LC-ESI/MS) + methods. As a result, three characteristic peaks ([M] and fragments from the Cβ-Cα bond breakage) were found to be unique and contained information useful in identifying 2C series compounds based on the GC-EI/MS method. We found that the protonated molecular ion ([M+H]+) and two types of fragments produced from the α-cleavage and β-cleavage processes were useful mass spectral information in the rapid screening and confirmation of phenethylamine and tryptamine derivatives when ESI/MS and MALDI/TOFMS methods were applied. This assay was successfully used to determine samples that contain illicit drugs. Keywords: phenethylamine; tryptamine; MALDI/TOFMS; GC-EI/MS; LC-ESI/MS 1. -
Precursors and Chemicals Frequently Used in the Illicit Manufacture Of
40 INCB REPORT ON PRECURSORS 2019 • 2,5-Dimethoxybenzaldehyde, a precursor for 2,5-dimethoxyamphetamine (DMA), brolamfetamine IV. Article 13 of the (DOB) and the 2C-series of controlled psychotropic substances, as well as for new psychoactive substances, 1988 Convention as reported by the Netherlands (5 kg) and Belgium (1 kg). a complementary tool in addressing • 4-Methoxy-P-2-P, a precursor of para-methoxy- alpha-methylphenethylamine (PMA) and para- illicit drug methoxymethylamphetamine (PMMA), reported by Spain (52 kg). manufacture 226. Through PICS, incidents involving 2-bromo- 4’-chloropropiophenone, a precursor of various 4-chloro- 229. The clandestine manufacture of narcotic drugs and substituted cathinone derivatives, such as 4-CMC psychotropic substances, new psychoactive substances and (clephedrone), were communicated. Luxembourg seized precursors is not possible without the input of chemicals, 500 kg of the substance in August 2018. The consignment materials and equipment. While the control of chemicals was confiscated because both the supplier and the con- has long been a focus of the authorities worldwide, pursu- signee were already known in connection with shipments ant to the provisions in article 12 of the 1988 Convention, of other precursors of new psychoactive substances. It much less attention has been given to equipment and originated in India, transited Qatar, Luxembourg and materials and article 13 of that Convention, which pro- Germany and was destined for a consignee in Poland. A vides a basis for international action and cooperation in consignment of 300 kg of the substance was confiscated by such control efforts (see box 5). customs authorities in Germany in December 2018. -
One-Pot Syntheses of Irida-Polycyclic Aromatic Hydrocarbons† Cite This: Chem
Chemical Science View Article Online EDGE ARTICLE View Journal | View Issue One-pot syntheses of irida-polycyclic aromatic hydrocarbons† Cite this: Chem. Sci.,2019,10, 10894 a a a b a All publication charges for this article Yu Xuan Hu,‡ Jing Zhang,‡ Xiaoyan Wang, Zhengyu Lu, Fangfang Zhang, have been paid for by the Royal Society Xiaofei Yang,a Zhihua Ma,a Jun Yin, *a Haiping Xia b and Sheng Hua Liu *a of Chemistry Metalla-analogues of polycyclic aromatic hydrocarbons (PAHs) have captivated chemists with their fascinating structures and unique electronic properties. To date, metallabenzene, metallanaphthalene and metallaanthracene have been reported. Metalla-analogues with more complicated fused rings have rarely been reported. Herein, we have successfully synthesized a series of new iridafluoranthenes and fused-ring iridafluoranthenes ranging from pentacyclic to heptacyclic metallaaromatic hydrocarbons in Received 6th August 2019 high yields under mild reaction conditions for the first time. Their photophysical and redox properties Accepted 12th October 2019 were also explored using UV-vis spectroscopy and electrochemistry combined with TD-DFT DOI: 10.1039/c9sc03914g calculations. The present work may offer an important guideline for the design and construction of new rsc.li/chemical-science polycyclic metallaaromatic hydrocarbons and metalla-nanographenes. Creative Commons Attribution-NonCommercial 3.0 Unported Licence. Introduction carbeneiridium compound by using an intramolecular C–H activation reaction.6b In 2018, they further developed irida- Polycyclic aromatic hydrocarbons (PAHs), as important compo- phenanthrene, iridanaphthalene and iridaanthracene from nents in the eld of organic chemistry, have attracted a signi- their corresponding methoxy(alkenyl)carbeneiridium inter- * cant amount of attention due to their wide range of applications mediates via reactions of [IrCp Cl(NCMe) (PMe3)]PF6 with 8 in organic light-emitting diodes,1 eld-effect transistors2 and diarylpropargyl alcohols. -
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs
Pharmacology and Toxicology of Amphetamine and Related Designer Drugs U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES • Public Health Service • Alcohol Drug Abuse and Mental Health Administration Pharmacology and Toxicology of Amphetamine and Related Designer Drugs Editors: Khursheed Asghar, Ph.D. Division of Preclinical Research National Institute on Drug Abuse Errol De Souza, Ph.D. Addiction Research Center National Institute on Drug Abuse NIDA Research Monograph 94 1989 U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service Alcohol, Drug Abuse, and Mental Health Administration National Institute on Drug Abuse 5600 Fishers Lane Rockville, MD 20857 For sale by the Superintendent of Documents, U.S. Government Printing Office Washington, DC 20402 Pharmacology and Toxicology of Amphetamine and Related Designer Drugs ACKNOWLEDGMENT This monograph is based upon papers and discussion from a technical review on pharmacology and toxicology of amphetamine and related designer drugs that took place on August 2 through 4, 1988, in Bethesda, MD. The review meeting was sponsored by the Biomedical Branch, Division of Preclinical Research, and the Addiction Research Center, National Institute on Drug Abuse. COPYRIGHT STATUS The National Institute on Drug Abuse has obtained permission from the copyright holders to reproduce certain previously published material as noted in the text. Further reproduction of this copyrighted material is permitted only as part of a reprinting of the entire publication or chapter. For any other use, the copyright holder’s permission is required. All other matieral in this volume except quoted passages from copyrighted sources is in the public domain and may be used or reproduced without permission from the Institute or the authors.